Aliases & Classifications for Syncope

MalaCards integrated aliases for Syncope:

Name: Syncope 51 29 3 3

Summaries for Syncope

NINDS : 51 Syncope is a medical term used to describe a temporary loss of consciousness due to the sudden decline of blood flow to the brain. Syncope is commonly called fainting or “passing out.” If an individual is about to faint, he or she will feel dizzy, lightheaded, or nauseous and their field of vision may “white out” or “black out.”  The skin may be cold and clammy.  The person drops to the floor as he or she loses consciousness.  After fainting, an individual may be unconscious for a minute or two, but will revive and slowly return to normal.  Syncope can occur in otherwise healthy people and affects all age groups, but occurs more often in the elderly.  There are several types of syncope.  Vasovagal syncope usually has an easily identified triggering event such as emotional stress, trauma, pain, the sight of blood, or prolonged standing.  Carotid sinus syncope happens because of constriction of the carotid artery in the neck and can occur after turning the head, while shaving, or when wearing a tight collar.  Situational syncope happens during urination, defecation, coughing, or as a result of gastrointestinal stimulation.  Syncope can also be a symptom of heart disease or abnormalities that create an uneven heart rate or rhythm that temporarily affect blood volume and its distribution in the body.  Syncope isn’t normally a primary sign of a neurological disorder, but it may indicate an increased risk for neurologic disorders such as Parkinson’s disease, postural orthostatic tachycardia syndrome (POTS), diabetic neuropathy, and other types of neuropathy.  Certain classes of drugs are associated with an increased risk of syncope, including diuretics, calcium antagonists, ACE inhibitors, nitrates, antipsychotics, antihistamines, levodopa, narcotics, and alcohol.

MalaCards based summary : Syncope is related to sick sinus syndrome 1 and ventricular tachycardia, catecholaminergic polymorphic, 1. An important gene associated with Syncope is SLC6A2 (Solute Carrier Family 6 Member 2), and among its related pathways/superpathways are Transmission across Chemical Synapses and Vascular smooth muscle contraction. The drugs Amiodarone and Ranolazine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and brain, and related phenotypes are cardiovascular system and muscle

Related Diseases for Syncope

Diseases related to Syncope via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 292)
id Related Disease Score Top Affiliating Genes
1 sick sinus syndrome 1 31.2 KCNH2 KCNQ1 SCN5A
2 ventricular tachycardia, catecholaminergic polymorphic, 1 31.0 KCNH2 KCNJ2 KCNQ1 NPPB SCN5A
3 short qt syndrome 1 30.5 KCNH2 KCNJ2 KCNQ1 SCN5A
4 atrial fibrillation, familial, 3 29.8 CAV3 KCNH2 KCNQ1 SCN5A
5 jervell and lange-nielsen syndrome 29.8 CALM1 CAV3 KCNH2 KCNJ2 KCNQ1 SCN5A
6 atrial fibrillation, familial, 10 29.7 CAV3 KCNH2 KCNQ1 SCN5A
7 second-degree atrioventricular block 28.5 KCNH2 KCNQ1 NPPB SCN5A
8 syncope, familial vasovagal 12.1
9 ventricular extrasystoles with syncopal episodes - perodactyly - robin sequence 12.0
10 ventricular extrasystoles with syncope, perodactyly, and robin sequence 11.8
11 catecholaminergic polymorphic ventricular tachycardia 11.5
12 fainting 11.4
13 ventricular tachycardia, catecholaminergic polymorphic, 2 11.4
14 ventricular tachycardia, catecholaminergic polymorphic, 4 11.4
15 orthostatic intolerance 10.9
16 brugada syndrome 10.9
17 wolff-parkinson-white syndrome 10.9
18 postural hypotension 10.9
19 pulmonary hypertension 10.9
20 progressive familial heart block, type ii 10.7
21 long qt syndrome 9 10.7
22 sinoatrial node dysfunction and deafness 10.7
23 long qt syndrome-3 10.7
24 heart block, progressive, type ia 10.7
25 dementia, lewy body 10.7
26 cardiac arrhythmia, ankyrin-b-related 10.7
27 muscular dystrophy, limb-girdle, type 2x 10.7
28 long qt syndrome-11 10.7
29 long qt syndrome 2 10.7
30 long qt syndrome 1 10.7
31 long qt syndrome-10 10.7
32 long qt syndrome 13 10.7
33 sick sinus syndrome 3 10.7
34 long qt syndrome 12 10.7
35 long qt syndrome 6 10.7
36 long qt syndrome 5 10.7
37 andersen syndrome 10.7
38 atrial fibrillation, familial, 6 10.5
39 atrial standstill 2 10.5
40 cardiomyopathy, hypertrophic, 20 10.5
41 hyperinsulinemic hypoglycemia, familial, 7 10.5
42 atrial fibrillation, familial, 11 10.5
43 atrial standstill, digenic 10.5
44 cardiomyopathy, hypertrophic, 2 10.5
45 cardiomyopathy, dilated, 1aa, with or without lvnc 10.5
46 long qt syndrome 15 10.5
47 cardiomyopathy, familial hypertrophic, 9 10.5
48 cardiomyopathy, familial hypertrophic 10.5
49 cardiomyopathy, hypertrophic, 13 10.5
50 cardiomyopathy, hypertrophic, 8 10.5

Graphical network of the top 20 diseases related to Syncope:



Diseases related to Syncope

Symptoms & Phenotypes for Syncope

MGI Mouse Phenotypes related to Syncope:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.5 CAV3 KCNH2 KCNJ2 KCNQ1 NPPA SCN5A
2 muscle MP:0005369 9.1 CAV3 KCNH2 KCNJ2 KCNQ1 NPPA SCN5A

Drugs & Therapeutics for Syncope

Drugs for Syncope (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 237)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amiodarone Approved, Investigational Phase 4,Phase 3 1951-25-3 2157
2
Ranolazine Approved, Investigational Phase 4,Phase 2 142387-99-3, 95635-55-5 56959
3
Testosterone Approved, Investigational Phase 4 58-22-0 6013
4
Losartan Approved Phase 4 114798-26-4 3961
5
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
6
Amlodipine Approved Phase 4 88150-42-9 2162
7
Bisoprolol Approved Phase 4,Phase 3 66722-44-9 2405
8
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
9
Propranolol Approved, Investigational Phase 4,Phase 2 525-66-6 4946
10
Midodrine Approved Phase 4 133163-28-7, 42794-76-3 4195
11
Fludrocortisone Approved Phase 4 127-31-1 31378
12
Treprostinil Approved, Investigational Phase 4 81846-19-7 54786 6918140
13
Epoprostenol Approved Phase 4 61849-14-7, 35121-78-9 5280427 5282411
14
Methyltestosterone Approved Phase 4 58-18-4 6010
15
Atenolol Approved Phase 4 29122-68-7 2249
16
Donepezil Approved Phase 4 120014-06-4 3152
17
Angiotensin II Investigational Phase 4,Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
18 Sodium Channel Blockers Phase 4,Phase 3,Phase 2
19 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3
21 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3
22 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3
23 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3
24 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3
25 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2
26 Vasodilator Agents Phase 4,Phase 3,Phase 2
27 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
28 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
29 Potassium Channel Blockers Phase 4,Phase 3
30 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
31 Tezosentan Phase 4
32 Testosterone undecanoate Phase 4
33
Testosterone enanthate Phase 4 315-37-7 9416
34 calcium channel blockers Phase 4
35 diuretics Phase 4,Phase 3,Phase 1,Phase 2
36 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Adrenergic Agonists Phase 4,Phase 1,Phase 2,Early Phase 1
38 Adrenergic alpha-Agonists Phase 4,Phase 1,Phase 2,Early Phase 1
39 Adrenergic Antagonists Phase 4,Phase 3,Phase 2
40 Adrenergic beta-1 Receptor Antagonists Phase 4,Phase 3
41 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 2,Phase 1
42 Natriuretic Agents Phase 4,Phase 3,Phase 1,Phase 2
43 Sodium Chloride Symporter Inhibitors Phase 4,Phase 3
44 Anabolic Agents Phase 4
45 Sympatholytics Phase 4,Phase 3
46 Testosterone 17 beta-cypionate Phase 4
47 Androgens Phase 4
48 Hormone Antagonists Phase 4
49 Hormones Phase 4,Phase 1,Phase 2
50 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 289)

id Name Status NCT ID Phase Drugs
1 Closed Loop Stimulation for Neuromediated Syncope (SPAIN Study) Unknown status NCT01621464 Phase 4
2 Safety of Amiodarone and Ranolazine Together in Patients With Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo
3 ISSUE3: International Study on Syncope of Uncertain Etiology 3 Completed NCT00359203 Phase 4
4 Clinical Trial for the Prevention of Vasovagal Syncope Completed NCT00118482 Phase 4 fludrocortisone acetate
5 ELIAS: Early Loop-Recorder in Suspected Arrhythmogenic Syncope Completed NCT00170261 Phase 4
6 Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance Completed NCT00060866 Phase 4 Propranolol
7 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01518946 Phase 4 Midodrine HCl;Placebo
8 Comparision of Blood Pressure Variability Between Amlodipine and Losartan Completed NCT01964079 Phase 4 Amlodipine;Losartan
9 Multicenter Automatic Defibrillator Implantation Trial - Reduce Inappropriate Therapy Completed NCT00947310 Phase 4
10 Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication Completed NCT00743522 Phase 4
11 Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis Completed NCT01133054 Phase 4
12 Effects of Testosterone on Myocardial Repolarization Completed NCT03126656 Phase 4 Testosterone Undecanoate
13 A Comparison of Polyglactin 910 and Chromic Gut Suture in the Closure of Punch Biopsy Sites Completed NCT01722994 Phase 4
14 Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin Completed NCT00373360 Phase 4 treprostinil sodium
15 Evaluation of PCLs Using Three EUS-FNA Needles Completed NCT01711294 Phase 4
16 Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV Recruiting NCT01456481 Phase 4 midodrine hydrochloride;matching placebo
17 Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Recruiting NCT02123056 Phase 4 Metoprolol;Matching Placebo
18 Combining Donepezil With Perceptual Learning in Normal and Amblyopic Human The Effect of Donepezil on Perceptual Learning in Adult Amblyopia Recruiting NCT03109314 Phase 4 Donepezil
19 Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART) Recruiting NCT03278509 Phase 4 Metoprolol Succinate;Bisoprolol
20 Syncope: Pacing or Recording in the Later Years Active, not recruiting NCT01423994 Phase 4
21 International Study on Syncope of Uncertain Etiology Terminated NCT00120094 Phase 4
22 A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension Terminated NCT00046163 Phase 4 midodrine hydrochloride (ProAmatine®)
23 Rapid Switch From Flolan to Remodulin in the Outpatient Clinic Terminated NCT00643604 Phase 4 treprostinil sodium
24 Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH Terminated NCT00439946 Phase 4 treprostinil
25 Adenosine Testing to DEtermine the Need for Pacing Therapy Unknown status NCT01481168 Phase 3
26 Lactobacillus Reuteri in Treatment of Functional Abdominal Pain and Chronic Constipation in Children Unknown status NCT01587846 Phase 3
27 Stop Vasodepressor Drugs in Reflex Syncope Completed NCT02137278 Phase 3 Vasoactive drug therapies
28 A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease Completed NCT01176240 Phase 3 Droxidopa
29 Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension Completed NCT00095550 Phase 3 Irbesartan/HCTZ;Irbesartan monotherapy;HCTZ monotherapy
30 Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension Completed NCT00095394 Phase 3 Irbesartan/HCTZ;Irbesartan monotherapy
31 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00633880 Phase 3 Placebo;Droxidopa
32 Ablation of Clinical Ventricular Tachycardia Versus Addition of Substrate Ablation on the Long Term Success Rate of VT Ablation Completed NCT01045668 Phase 3
33 Effects of PTH Replacement on Bone in Hypoparathyroidism Completed NCT00395538 Phase 3 PTH 1-34
34 Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD Completed NCT00532493 Phase 3 prazosin
35 Induction With Foley OR Misoprostol (INFORM) Study Completed NCT01801410 Phase 3 Misoprostol
36 Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity Completed NCT00323973 Phase 3 Bisoprolol
37 Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor Completed NCT00308711 Phase 3 Misoprostol vaginal insert 100 mcg;Misoprostol vaginal insert 50 mcg;Dinoprostone vaginal insert (Cervidil)
38 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Completed NCT00782340 Phase 3 Placebo;Droxidopa
39 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00738062 Phase 3 Droxidopa;Placebo
40 Efficacy of Transcatheter Ablation Using Anatomic Approach of Ganglionated Plexi Located in the Right Atrium to Prevent Neuromediated Cardioinhibitory Syncope Recruiting NCT01814228 Phase 3
41 Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections. Recruiting NCT02809131 Phase 3 polymixin/bacitracin;cephalexin, or levofloxacin, or clindamycin;Saline
42 Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction Recruiting NCT00673842 Phase 3
43 Ballooned Intercostal Drain Trial Not yet recruiting NCT03000504 Phase 3
44 Traumatic Optic Neuropathy Treatment Trial 2 Not yet recruiting NCT03308448 Phase 3 Recombinant human erythropoietin
45 Effect of Chronic Oral Hydration in Patients With Recurrent Unexplained Syncope Terminated NCT00143754 Phase 3
46 A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy Terminated NCT01927055 Phase 3 Droxidopa;Placebo
47 Hydroquinidine Versus Placebo in Patients With Brugada Syndrome Terminated NCT00927732 Phase 3 hydroquinidine;placebo (sugar)
48 Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy Withdrawn NCT01560091 Phase 3 silodosin;Tamsulosin
49 Evaluate the Noninferiority of Medicines Treating Uninfected Pressure Ulcers. Withdrawn NCT02004626 Phase 3 Collagenase;Kollagenase
50 Trial Comparing Ablation With Medical Therapy in Patients With Ventricular Tachycardia Withdrawn NCT01798277 Phase 3 Medical therapy (sotalol or amiodarone)

Search NIH Clinical Center for Syncope

Genetic Tests for Syncope

Genetic tests related to Syncope:

id Genetic test Affiliating Genes
1 Syncope 29

Anatomical Context for Syncope

MalaCards organs/tissues related to Syncope:

39
Heart, Testes, Brain, Thyroid, Skin, Liver, Bone

Publications for Syncope

Articles related to Syncope:

(show top 50) (show all 913)
id Title Authors Year
1
Prevalence of Pulmonary Embolism in Patients Presenting to the Emergency Department for Syncope. ( 28759507 )
2017
2
Recurrent syncope due to glossopharyngeal neuralgia. ( 28491772 )
2017
3
Dose-Response Relationship between the Risk of Vasovagal Syncope and Body Mass Index or Systolic Blood Pressure in Young Adults Undergoing Blood Tests. ( 28810256 )
2017
4
Prevalence of pulmonary embolism in patients presenting with syncope. A systematic review and meta-analysis. ( 28947223 )
2017
5
The effects of body weight status on orthostatic intolerance and predisposition to noncardiac syncope. ( 28112481 )
2017
6
Impact of pharmacological spasm provocation test in patients with a history of syncope. ( 28905210 )
2017
7
Discriminatory Value of Orthostatic Vital Signs in the Emergency Department Evaluation of Syncope. ( 28844271 )
2017
8
Giant Left Atrial Myxoma Masquerading as Cough-Syncope Syndrome. ( 28815190 )
2017
9
Perservative paroxysmal atrioventricular block : Cardiac syncope misdiagnosed as anxiety for more than 20A years. ( 28840364 )
2017
10
Effect of Citalopram for the Treatment of Neurocardiogenic Syncope. ( 28816725 )
2017
11
Bradycardia, Syncope, and Left Ventricular Noncompaction Cardiomyopathy. ( 28645472 )
2017
12
Comparison of Specific Fainting Characteristics Between Youth With Tilt-Induced Psychogenic Nonsyncopal Collapse Versus Reflex Syncope. ( 28236458 )
2017
13
Syncope During Competitive Events: Interrogating Heart Rate Monitor Watches May Be Useful! ( 28807079 )
2017
14
Experience of a rapid access falls and syncope service at a teaching hospital in Kuala Lumpur. ( 28889130 )
2017
15
Cor triatriatum sinistrum: presentation of syncope and atrial tachycardia. ( 28196823 )
2017
16
Syndromes of orthostatic intolerance and syncope in young adults. ( 28674628 )
2017
17
Prevalence of pulmonary embolism in patients presenting to the emergency department with syncope. ( 28811209 )
2017
18
Role of closed loop stimulation pacing (CLS) in vasovagal syncope. ( 28895151 )
2017
19
Acute onset autonomic dysfunction and orthostatic syncope as an early manifestation of HIV infection. ( 28856462 )
2017
20
Masquerading bundle branch block as a presenting manifestation of complete atrioventricular block that caused syncope. ( 28627977 )
2017
21
Sniffing and gasping to prevent syncope? ( 28863464 )
2017
22
Syncope and orthostatic hypotension: early markers of cardiac disease in the general population. ( 28814494 )
2017
23
Late-onset Pompe disease in a 54 year-old sportsman with an episode of syncope: a case report. ( 28925476 )
2017
24
Syncope Due to a Free-floating Left Atrial Thrombus. ( 28943579 )
2017
25
The Use of Echocardiography for Pediatric Patients Presenting with Syncope. ( 28888565 )
2017
26
Use of Biotronik closed loop pacemaker to treat recurrent syncope in pediatric patient with dysautonomia. ( 28491761 )
2017
27
Stressful medical explanation may cause syncope in patients with emotion-triggered neurocardiogenic syncope. ( 28925543 )
2017
28
Primary Cardiac Sarcoidosis with Syncope and Refractory Atrial Arrhythmia: A Case Report and Review of the Literature. ( 27303240 )
2016
29
Syncope With Profound Bradycardia. ( 27134236 )
2016
30
An Experimental Model of Vasovagal Syncope Induces Cerebral Hypoperfusion and Fainting-Like Behavior in Awake Rats. ( 27658057 )
2016
31
Syncope on a Hot Summer Day. ( 27131612 )
2016
32
A rare cause of syncope in a young female. ( 27567040 )
2016
33
Accessory Liver in the Right Atrium: A Rare Cause of Syncope. ( 27549551 )
2016
34
Syncope in older adults. ( 27594863 )
2016
35
Thrombosis of Inferior Vena Cava Diagnosed Using Point-of-Care Ultrasound After Pediatric Near-Syncope. ( 27545854 )
2016
36
The Cost-Effective Evaluation of Syncope. ( 27542422 )
2016
37
Intracardiac Leiomyomatosis - an Unusual Cause of Syncope in a Middle-Aged Woman. ( 27743856 )
2016
38
Syncope: Not for the faint hearted. ( 27189260 )
2016
39
Implantable loop recorder versus conventional diagnostic workup for unexplained recurrent syncope. ( 27092427 )
2016
40
From syncope episode to the diagnosis of ovarian dermoid cyst associated with a cystadenoma. ( 26968295 )
2016
41
Pathophysiological mechanisms of noncardiac syncope in athletes. ( 27606909 )
2016
42
Stop vasodepressor drugs in reflex syncope: a randomised controlled trial. ( 27664002 )
2016
43
Management of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia and Vasovagal Syncope. ( 27617091 )
2016
44
Reduced compensatory responses to maintain central blood volume during hypovolemic stress in women with vasovagal syncope. ( 27654398 )
2016
45
Early onset brain calcifications secondary to hypoparathyroidism in a boy with syncopal-like symptomatology. ( 27909973 )
2016
46
Syncope Following Orthotopic Heart Transplant: Sinoatrial or Atrioventricular Nodal Block? ( 27214093 )
2016
47
77-year-old female with syncope. ( 27664004 )
2016
48
The mechanism of syncope without prodromes with normal heart and normal electrocardiogram. ( 27639455 )
2016
49
The Current Indication for Pacemaker in Patients with Cardioinhibitory Vasovagal Syncope. ( 27651841 )
2016
50
Syncope (Fainting). ( 27142609 )
2016

Variations for Syncope

Expression for Syncope

Search GEO for disease gene expression data for Syncope.

Pathways for Syncope

Pathways related to Syncope according to GeneCards Suite gene sharing:

(show all 15)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.69 CALM1 GNB3 KCNH2 KCNJ2 KCNQ1
2
Show member pathways
12.53 CALM1 KCNJ2 KCNQ1 NPPB SCN5A
3
Show member pathways
12.45 CALM1 GNB3 KCNJ2 KCNQ1
4
Show member pathways
12.17 GNB3 NPPA NPPB
5 12.01 CALM1 GNB3 KCNH2 KCNJ2 KCNQ1
6
Show member pathways
11.92 CALM1 KCNJ2 KCNQ1
7
Show member pathways
11.89 CALM1 CAV3 KCNH2 KCNJ2 KCNQ1 NPPA
8
Show member pathways
11.87 CALM1 NPPA NPPB
9
Show member pathways
11.79 GNB3 KCNH2 KCNJ2 KCNQ1
10 11.57 CAV3 GNB3 KCNH2 KCNQ1 SCN5A
11
Show member pathways
11.46 CALM1 KCNQ1 SCN5A
12 11.2 KCNH2 KCNJ2 KCNQ1 SCN5A
13 11.09 CALM1 CAV3
14 10.85 NPPA NPPB
15 10.74 KCNJ2 KCNQ1

GO Terms for Syncope

Cellular components related to Syncope according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.56 CAV3 KCNH2 SCN5A SLC6A2
2 membrane raft GO:0045121 9.5 CAV3 KCNQ1 SLC6A2
3 voltage-gated potassium channel complex GO:0008076 9.33 KCNH2 KCNJ2 KCNQ1
4 intercalated disc GO:0014704 9.13 CAV3 KCNJ2 SCN5A
5 T-tubule GO:0030315 8.8 CAV3 KCNJ2 SCN5A

Biological processes related to Syncope according to GeneCards Suite gene sharing:

(show all 39)
id Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.98 KCNH2 KCNJ2 KCNQ1 SCN5A
2 transmembrane transport GO:0055085 9.97 KCNH2 KCNQ1 SCN5A SLC6A2
3 protein folding GO:0006457 9.84 GNB3 NPPA NPPB
4 potassium ion transmembrane transport GO:0071805 9.83 KCNH2 KCNJ2 KCNQ1
5 potassium ion transport GO:0006813 9.82 KCNH2 KCNJ2 KCNQ1
6 regulation of ion transmembrane transport GO:0034765 9.8 KCNH2 KCNJ2 KCNQ1 SCN5A
7 regulation of blood pressure GO:0008217 9.71 GNB3 NPPA NPPB
8 cardiac muscle contraction GO:0060048 9.69 KCNH2 KCNQ1 SCN5A
9 regulation of heart contraction GO:0008016 9.68 CAV3 KCNQ1
10 membrane depolarization during action potential GO:0086010 9.67 KCNH2 SCN5A
11 cardiac conduction GO:0061337 9.67 KCNH2 KCNJ2 KCNQ1 SCN5A
12 cGMP biosynthetic process GO:0006182 9.66 NPPA NPPB
13 regulation of cardiac muscle contraction GO:0055117 9.66 CALM1 CAV3
14 positive regulation of heart rate GO:0010460 9.65 KCNQ1 NPPA
15 regulation of heart rate GO:0002027 9.65 CALM1 CAV3 SCN5A
16 regulation of blood vessel size GO:0050880 9.64 NPPA NPPB
17 cardiac muscle cell action potential involved in contraction GO:0086002 9.63 KCNJ2 SCN5A
18 regulation of cardiac muscle cell contraction GO:0086004 9.63 KCNJ2 SCN5A
19 positive regulation of potassium ion transmembrane transport GO:1901381 9.63 KCNH2 KCNJ2 KCNQ1
20 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.62 KCNJ2 SCN5A
21 positive regulation of cardiac muscle contraction GO:0060452 9.61 KCNQ1 NPPA
22 receptor guanylyl cyclase signaling pathway GO:0007168 9.61 NPPA NPPB
23 regulation of membrane repolarization GO:0060306 9.61 KCNH2 KCNJ2 KCNQ1
24 atrial cardiac muscle cell action potential GO:0086014 9.6 KCNQ1 SCN5A
25 negative regulation of potassium ion transmembrane transport GO:1901380 9.59 CAV3 KCNH2
26 potassium ion export GO:0071435 9.58 KCNH2 KCNQ1
27 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.58 KCNH2 KCNJ2 KCNQ1
28 regulation of ventricular cardiac muscle cell membrane depolarization GO:0060373 9.57 CAV3 SCN5A
29 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.56 KCNH2 KCNQ1
30 regulation of heart rate by cardiac conduction GO:0086091 9.56 KCNH2 KCNJ2 KCNQ1 SCN5A
31 cellular response to mechanical stimulus GO:0071260 9.55 KCNJ2 NPPA
32 potassium ion export across plasma membrane GO:0097623 9.52 KCNH2 KCNQ1
33 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.5 KCNQ1 NPPA SCN5A
34 cell growth involved in cardiac muscle cell development GO:0061049 9.34 NPPA
35 membrane repolarization during action potential GO:0086011 9.33 KCNH2 KCNJ2 KCNQ1
36 membrane repolarization GO:0086009 9.32 KCNQ1
37 negative regulation of systemic arterial blood pressure GO:0003085 9.28 NPPA
38 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.26 CAV3 KCNH2 KCNQ1 SCN5A
39 ventricular cardiac muscle cell action potential GO:0086005 8.92 CAV3 KCNH2 KCNQ1 SCN5A

Molecular functions related to Syncope according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 alpha-tubulin binding GO:0043014 9.48 CAV3 SLC6A2
2 delayed rectifier potassium channel activity GO:0005251 9.46 KCNH2 KCNQ1
3 voltage-gated ion channel activity GO:0005244 9.46 KCNH2 KCNJ2 KCNQ1 SCN5A
4 inward rectifier potassium channel activity GO:0005242 9.43 KCNH2 KCNJ2
5 scaffold protein binding GO:0097110 9.43 KCNH2 KCNQ1 SCN5A
6 nitric-oxide synthase binding GO:0050998 9.4 CAV3 SCN5A
7 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.32 KCNH2 KCNQ1
8 ion channel binding GO:0044325 9.26 CALM1 CAV3 KCNQ1 SCN5A
9 peptide hormone receptor binding GO:0051428 9.07 NPPA
10 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 8.8 KCNH2 KCNJ2 KCNQ1

Sources for Syncope

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....